Articles tagged with Crohn Disease
Researchers discovered that CEACAM6 facilitates adhesion of adherent-invasive E. coli (AIEC) bacteria to the intestinal epithelial cells' brush border in patients with Crohn's disease. This adhesion is dependent on CEACAM6 expression, which is increased in Crohn's disease patients after infection.
A long-term study of REMICADE found that patients with moderate to severe ulcerative colitis maintained improved clinical symptoms for up to two years after treatment. The study showed that 92% of patients had mild or no disease activity at week 56 and 97% at week 104, indicating sustained efficacy.
A study by Mayo Clinic found that adalimumab is an effective treatment for adults with Crohn’s disease who do not respond to infliximab therapy. The therapy was shown to achieve remission in 21% of patients and improve symptoms in 52%.
Researchers have discovered a new genetic locus associated with an increased risk of developing Crohn's disease, a chronic inflammatory disorder. The study, published in PLOS Genetics, found that a specific region on chromosome 5 is linked to the disease.
A consortium of Canadian and American researchers have identified three major genetic risk factors for Crohn's disease: PHOX2B, NCF4, and ATG16L1. These findings highlight biological pathways not previously thought to play a role in the disease, including altered reactive oxygen species production and autophagic processes.
A research team has identified several novel genetic variations associated with the risk of Crohn's disease, which could improve understanding of the disease process and lead to new therapies. The study found that one of the newly identified genes, ATG16L1, plays a crucial role in autophagy, a biological pathway involved in inflammation.
A study published in Nature Genetics identifies PHOX2B, NCF4, and ATG16L1 as genetic risk factors for Crohn's disease. The research highlights the role of neuroendocrine cells and altered reactive oxygen species production in increasing disease susceptibility.
Researchers identify three genetic variants associated with an increased risk of Crohn's disease, including PHOX2B, NCF4, and ATG16L1. These discoveries offer new insights into the biological pathways underlying the disease and may lead to more effective therapies.
Patients treated with REMICADE experienced significant improvements in work and daily activities, with mean increases of 2.9-3.1 points compared to little improvement in placebo-treated patients. Psoriasis is an inflammatory disorder that can cause physical pain and emotional distress, impacting productivity.
A Penn State College of Medicine pilot study found that 89 percent of participants with diagnosed Crohn's disease showed improvement with low-dose naltrexone therapy, while 67 percent achieved remission. This novel approach offers a simple and safe treatment option for the chronic inflammatory disorder.
Research reveals IBD increases risk of premature birth and low birthweight by almost twice, while also boosting caesarean section rates and congenital defects
A CCFA survey reveals that 65% of ulcerative colitis patients are less than fully compliant with first-line therapies, resulting in a significant impact on their quality of life. The most common reasons for non-compliance were dosing frequency, number of pills, and medication inconvenience.
Researchers have discovered a genetic risk factor for inflammatory bowel disease (IBD) that may confer protection against Crohn's disease and ulcerative colitis. The study highlights a major inflammatory pathway and identifies potential targets for therapies, including the manipulation of IL-23 pathway.
A recent study has identified a new genetic link to Crohn's disease, revealing that mutations in the IL-23 receptor gene are strongly associated with the condition. The researchers found that one type of mutation provides significant protection, paving the way for more individualized and effective treatments.
A study by Yale researchers has identified a gene variant associated with Crohn's disease, which may offer new therapeutic targets for the condition. The discovery was made in collaboration with international researchers who scanned the genome of over 300,000 individuals to identify genetic components of inflammatory bowel disease.
The study identified two genes linked to Crohn's disease: Nod2 and IL-23R. This discovery may lead to improved diagnosis and targeted drug therapies for patients with Crohn's disease.
An international team of researchers has identified a novel gene mutation linked to Crohn's disease and ulcerative colitis, which may offer a new pathway for tracking the disease process and potential drug treatments.
A new genetic link has been found for Crohn's disease, revealing a crucial target for drugs that might better manage the condition. The discovery of a specific gene variant confers significant protection against IBD, suggesting therapies targeting the IL-23 pathway may lead to more individualized treatments.
A recent study by Penn State researchers found that 89% of patients with diagnosed Crohn's disease showed improvement with therapy using naltrexone, while 67% achieved remission of symptoms. The treatment has been shown to be simple, safe, and cost-effective compared to traditional steroid treatments.
Researchers investigated TLR5 gene variants and their relationship to Crohn's Disease, finding effects on both Jews and non-Jews. The study highlights the importance of considering ethnicity in future investigations for better therapies.
Recent studies have found that biologic therapies, such as adalimumab and certolizumab pegol, can effectively maintain clinical remission and response in patients with moderately to severely active Crohn's disease. These treatments have shown fewer side effects compared to traditional medications.
A new study reviews the therapeutic benefits of lubiprostone for c-IBS patients, showing improvements in abdominal discomfort and bowel movements. Teduglutide is also found to be effective in inducing remission and response in patients with moderate or severe Crohn's disease.
The FDA has granted a priority review of REMICADE for the treatment of children with moderately to severely active Crohn's disease. In the REACH trial, nearly 90% of pediatric patients achieved clinical response at week 10 and over half were in clinical remission at one year.
The Crohn's & Colitis Foundation of America has partnered with John Wiley & Sons, Inc. to publish the peer-reviewed journal Inflammatory Bowel Diseases. The journal will provide a platform for researchers and clinicians to share advances in the treatment and mechanisms of Crohn's disease and ulcerative colitis.
Researchers found that Crohn's disease patients produce lower quantities of neutrophils and inflammatory mediators in response to trauma, leading to delayed blood flow and persistence of bacteria. Treatment with Viagra corrected abnormally low blood flow, suggesting a potential role for the drug in treating the disease.
A recent study published in American Journal of Roentgenology found that CT enteroclysis can detect complications like fistulas, abscesses, and tumors superior to conventional enteroclysis. This imaging method also detects minimal mucosal changes, a sign of early stage Crohn's disease, with no disadvantages.
The Voices of UC survey highlights the extensive impact of ulcerative colitis on patients' lives, including work, family, and social activities. The study found that nearly half of patients believe their condition is underestimated and misunderstood by others.
The PRECiSE 2 study found that patients treated with CIMZIA achieved a higher clinical response and remission rate compared to those receiving placebo. The study demonstrated the efficacy of CIMZIA in maintaining clinical response after induction therapy, with a significant proportion of patients able to achieve remission by week 26.
A team of scientists at Sanford Burnham Prebys found that an antibody produced in reaction to a naturally-occurring sugar chain curbs intestinal inflammation induced in mice, reversing early symptoms and halting disease progression. The research holds promise for treating Crohn's disease and other inflammatory disorders.
Research confirms that patients with inflammatory bowel disease (IBD) are more likely to develop conditions such as asthma, multiple sclerosis, and other demyelinating disorders. The studies found a nearly two-fold increased risk of multiple sclerosis in IBD patients, highlighting the need for closer monitoring.
A comprehensive analysis of gene expression revealed that 650 genes differ between normal individuals and patients with ulcerative colitis or Crohn disease. Down-regulation, rather than up-regulation, was the prevailing pattern found in both diseases.
Researchers found that GM-CSF treatment alleviated symptoms of Crohn's disease and improved patients' quality of life, with significantly less inflammation in the mucosal linings. The study showed a 40% remission rate for those receiving the drug compared to 19% of placebo recipients.
Researchers found that GM-CSF treatment significantly improved Crohn's disease symptoms in patients, suggesting a defect in innate immune system is the underlying cause. The study supports a new understanding of Crohn's and offers hope for a new treatment option.
Researchers found that rifaximin significantly improved disease activity in patients with Crohn's disease. The analysis of 8 patients showed a mean decrease in Harvey Bradshaw index of 7.1, indicating potential effectiveness as a treatment.
Recent clinical trials have shown promising results for biologic therapies in treating Crohn's disease, with Alequel achieving high clinical remission rates. Additionally, a study on adalimumab has demonstrated increased efficacy over time, while maintaining a strong safety profile.
A study published in Science identified interleukin-1Beta (IL-1â) as a major cause of severe inflammation in mouse models of Crohn's disease, which is a chronic inflammatory bowel disease affecting over 500,000 Americans. High levels of IL-1â were found in mice with mutant NOD2, a genetic defect linked to 50% of Crohn's cases.
Researchers at the University of Alberta found that adding calcium and vitamin D therapy alone provides significant benefit for patients with Crohn's disease who suffer from osteoporosis or osteopenia. The study concluded that physicians should consider BMD testing and drug therapy only for high-risk patients, not those with mild Crohn...
The IBDchip is an open tool that includes polymorphisms associated with the disease, predisposition, and evolution. Progenika has developed similar products, including the Lipochip for hypercholesterolemia diagnosis and the Bloodchip for genotyping blood donors.
Research reveals NOD2 activation leads to modification of NEMO, a central component of the NF-kB signaling pathway controlling inflammatory responses. This discovery suggests a potential pharmacological target for Crohn's Disease treatment.
Researchers challenge traditional hypotheses on Crohn's disease, suggesting a more complex role for cytokines in the immune response. This could lead to new treatment strategies involving the blockade of multiple cytokines.
A new antibody treatment has shown promise in slowing or halting Crohn's disease by blocking the production of inflammatory proteins. The treatment was safe and effective in reducing symptoms in patients with active Crohn's disease.
A study finds that 50% of patients with Crohn's disease have viable MAP in their blood, suggesting a systemic infection. The findings raise questions about the role of MAP in IBD and highlight the need for further research to clarify its significance.
Researchers found that growth hormone reduces STAT3 activation, modulates cellular apoptosis and proliferation, and improves weight gain in mice with colitis. The study suggests using growth hormone as a new therapeutic approach to improve growth and intestinal healing in IBD.
Researchers have found that adding butyrate to an intravenous nutrition solution can cause the intestine to grow back and become more functional. This breakthrough offers hope for preterm infants and patients with Crohn's disease who rely on IV feeding due to surgically removed intestines.
A Phase III maintenance trial of natalizumab found sustained clinical response and remission rates among patients with Crohn's disease. The study also showed that a majority of patients on corticosteroids were able to withdraw from the medication without losing their response.
Researchers have found that natalizumab and adalimumab can help maintain clinical response and remission in patients with Crohn's disease. A trial also investigated the use of helminth ova as a potential treatment, showing significant improvements in clinical response and remission.
Researchers found that among patients with confirmed Crohn's disease, clinical decisions based on capsule endoscopy findings improved outcomes in 95% of patients. Capsule endoscopy was also 100 percent effective in excluding a diagnosis of Crohn's disease.
U of T researchers identify gene responsible for protein malfunction in Crohn's patients, enabling diagnostic test and potential new treatments. The findings provide valuable insights into chronic inflammation and its impact on the disease.
A study published in Inflammatory Bowel Diseases found that gadolinium-enhanced MRI (G-MRI) was highly accurate in diagnosing inflammatory bowel disease (IBD) in children, with 92% accuracy for ulcerative colitis and 96% accuracy for Crohn's disease. This non-invasive diagnostic tool could replace conventional tests like colonoscopy.
A study led by Massachusetts General Hospital found that infliximab can heal and reduce the recurrence of fistulas in Crohn's disease patients. The treatment, which targets tumor necrosis factor, showed significant benefits in closing fistulas and improving quality of life.
Researchers discover a variant of the NFKB1 gene associated with ulcerative colitis, a condition characterized by intestinal inflammation. Additionally, a second study links the MDR1 gene to Crohn's disease and possibly ulcerative colitis.
The cold-chain hypothesis proposes that psychrotrophic bacteria in refrigerated foods contribute to Crohn's disease. These bacteria have been identified in disease lesions and may trigger excessive host responses.
Researchers identified TL1A, a cytokine that regulates immune response, as a potential target for treating IBD. The protein's expression correlated with inflammation severity in Crohn's disease, but not ulcerative colitis.
Researchers at Temple University have identified a genetic mutation responsible for inflammation in Crohn's disease. The study found that a specific protein, kininogen, plays a key role in the development of the disease.
Researchers found that intestinal bacteria in the terminal ileum activate p40 expression, leading to chronic inflammation and predisposing this region to Crohn's disease. The study provides a molecular explanation for why Crohn's disease often affects the small intestine.
A new multi-center study confirms the effectiveness and safety of infliximab in treating pediatric Crohn's disease, leading to significant short-term medical benefits and a reduced need for steroids. The study shows improved symptoms such as pain, growth rates, and bowel movements, with no adverse reactions at infusion sites.
In the Phase II study, natalizumab demonstrated higher rates of clinical remission compared to placebo at multiple time points. The highest rate of remission was observed in the dual 3 mg/kg dose group, with a maximal response of 71%.
Researchers found that patients with moderate to severe Crohn's disease improved significantly after receiving GM-CSF, with 12 out of 15 patients in clinical remission. The treatment targets the innate immune response and has shown promise as an alternative approach to traditional therapies.
A study of 355 patients with severe Crohn's disease found that infliximab treatment every two months significantly increased remission rates compared to placebo. Infliximab also allowed patients to taper off steroids and maintain clinical remissions.
A multi-center research team found that infliximab prolonged remissions in moderate to severe Crohn's disease patients by twice as long at bi-monthly infusions compared to every eight weeks. The drug also helped patients reduce steroid use and improve quality of life.